Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7289 USD | -2.68% | +2.71% | +27.25% |
03-14 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-14 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Business Summary
Number of employees: 109
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Recombinant Protein Vaccines
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 31/12/03 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 18/12/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
James Cummings
CTO | Chief Tech/Sci/R&D Officer | - | 26/09/21 |
Chief Tech/Sci/R&D Officer | - | 30/08/22 | |
Edward Berg
LAW | General Counsel | - | 13/02/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 24/10/19 |
Elaine Heron
BRD | Director/Board Member | 76 | 24/08/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
Sean Tucker
FOU | Founder | - | 31/12/03 |
David Wheadon
BRD | Director/Board Member | 66 | 20/04/21 |
Director/Board Member | 73 | 03/08/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 177,345,031 | 174,833,551 ( 98.58 %) | 507,020 ( 0.2859 %) | 98.58 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.25% | 129M | |
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- VXRT Stock
- Company Vaxart, Inc.